Results 11 to 20 of about 13,851 (214)

Sclerostin and Cardiovascular Disease

Current Osteoporosis Reports, 2023
Purpose of ReviewThe role of wnt signalling in atherogenesis raises the possibility that the wnt inhibitor, sclerostin, provides a natural defence to this process, and that anti-sclerostin antibodies might increase the risk of atherosclerosis and ...
Tobias, Jonathan H, Jonathan H. Tobias
core   +4 more sources

Sclerostin and Vascular Pathophysiology [PDF]

International Journal of Molecular Sciences, 2020
There is cumulating evidence for a contribution of Wnt signaling pathways in multiple processes involved in atherosclerosis and vascular aging. Wnt signaling plays a role in endothelial dysfunction, in the proliferation and migration of vascular smooth ...
Catalano, Corica, Morabito, Bellone, Bellone F., Catalano A., Corica F., Morabito N.   +7 more
core   +4 more sources

Sclerostin [PDF]

Journal of Osteoporosis, 2010
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents.
Stuart L. Silverman
core   +5 more sources

The Role of Sclerostin in Bone Diseases [PDF]

Journal of Clinical Medicine, 2022
Sclerostin has been identified as an important regulator of bone homeostasis through inhibition of the canonical Wnt-signaling pathway, and it is involved in the pathogenesis of many different skeletal diseases.
Pneumaticos, Spyros G., Vlachos, Christos, Vasiliadis, Elias S., Evangelopoulos, Dimitrios-Stergios, Benetos, Ioannis S., Kaspiris, Angelos   +5 more
core   +5 more sources

Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism

Nature Communications
Sclerostin, which has three loops, inhibits bone formation and impairs whole-body lipid and glucose metabolism. The marketed therapeutic sclerostin antibody for postmenopausal osteoporosis (POP) mainly targeting loop2 promotes bone formation and improves
Hewen Jiang, Xiaohui Tao, Sifan Yu, Yihao Zhang, Yuan Ma, Nanxi Li, Shenghang Wang, Ning Zhang, Xin Yang, Shijian Ding, Chuanxin Zhong, Haitian Li, Zhanghao Li, Xiaoxin Wen, Huarui Zhang, Zefeng Chen, Meiheng Sun, Hang Luo, Meishen Ren, Chongguang Lei, Yuanyuan Yu, Jin Liu, Zongkang Zhang, Aiping Lyu, Hui Sheng, Dijie Li, Luyao Wang, Ge Zhang, Bao-Ting Zhang   +28 more
doaj   +2 more sources

Anti-sclerostin antibody – A potential therapeutic target for periodontal bone regeneration

Journal of Oral Research and Review
Sclerostin is a glycoprotein predominantly released by specialized bone-forming cells (osteocytes). It serves as a principal inhibitor of osteogenesis and plays a key act in modulating the metabolism of alveolar bone. Sclerostin is shown to contribute to
Shruthi Reghunath, Roshni Ramesh, Raseena Beevi Nafeesa, Divya Purushothaman Visalakshy, Binitta Paul Kannappillil, Ambili Gopalakrishnan   +5 more
doaj   +2 more sources

Role of Sclerostin in Cardiovascular System

International Journal of Molecular Sciences
Sclerostin, encoded by the SOST gene, is a novel bone anabolic target for bone diseases. Humanized anti-sclerostin antibody, romosozumab, was approved for treatment of postmenopausal osteoporosis by the US Food and Drug Administration (FDA), but with a ...
Hewen Jiang, Jin Liu, Yuan Ma, Luyao Wang, Xiaofei Li, Ge Zhang, Xin Yang, Ning Zhang, Baoting Zhang, Sifan Yu, Xiaohui Tao, Yuanyuan Yu   +11 more
core   +3 more sources

Macrophagic Sclerostin Loop2‐ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action

Advanced Science
Therapeutic antibody against sclerostin loop2 promoted bone formation in postmenopausal osteoporosis but caused severe cardiovascular events in clinical applications.
Luyao Wang, Xiaohui Tao, Ning Zhang, Xin Yang, Hewen Jiang, Xiaofei Li, Shenghang Wang, Shijian Ding, Sifan Yu, Huarui Zhang, Yihao Zhang, Nanxi Li, Haitian Li, Zhanghao Li, Xiaoxin Wen, Meiheng Sun, Chuanxin Zhong, Jin Liu, Yuanyuan Yu, Xianghang Luo, Tao Zhang, Shu Zhang, Péter Ferdinandy, Yu Huang, Daqing Ma, Aiping Lu, Baoting Zhang, Ge Zhang   +27 more
doaj   +3 more sources

Sclerostin as a new target of diabetes-induced osteoporosis [PDF]

Frontiers in Endocrinology
Sclerostin, a protein synthesized by bone cells, is a product of the SOST gene. Sclerostin is a potent soluble inhibitor of the WNT signaling pathway, and is known to inhibit bone formation by inhibiting osteocyte differentiation and function. Currently,
Yanhua Li, Yaheng Luo, Debin Huang, Lele Peng   +3 more
doaj   +2 more sources

Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis

International Journal of Women's Health, 2015
Arti D Shah,1 Dolores Shoback,1,2 E Michael Lewiecki3,4 1Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Francisco, CA, USA; 2Endocrine Research Unit, Department of Medicine, Veterans Affairs Medical ...
Shah AD, Shoback D, Lewiecki EM
doaj   +1 more source